By John Russell
July 20, 2005 | Towards the end of this summer, Jeremy Gunawardena and Aneil Mallavarapu of the Virtual Cell Program at Harvard Medical School’s Department of Systems Biology expect to unleash b — pronounced “little b” — a new open-source computer language they hope will energize the biological modeling community as nothing has before.
Today, a handful of companies and academic groups are building computational models of disease and biological pathways. To a considerable extent, these scattered efforts remain in their infancy (although modeling has recently gained traction inside a few biopharmas). Moreover, the companies charge for their services and tools and have a vested interest in controlling their proprietary technology. On balance, there has been little synergy between these isolated pockets of progress.
Imagine instead a biologist-friendly language designed specifically to encapsulate biological knowledge and constantly pounded on and improved upon by an open-source community. Add to this vision a growing library of models (and model fragments) written in b and contributed by researchers worldwide for free use by other researchers. Based on list processing (LISP), b is designed to be modular, emphasizing the reusability of modules and a Lego-like approach to model building.
Currently, b focuses on biochemical modeling using ordinary differential equations. However, Mallavarapu says, “We want to expand to describe other types of models like partial differential equations, and we’re working on what it will take to write stochastic models.”
It’s not a great leap to conceive of a GenBank for computational models that researchers could contribute to and draw from. Imagine the interesting and productive in silico research that an army of modelers might undertake.
This is a grand vision for a language with such a diminutive name, and it is one of the first concrete projects emerging from Harvard’s ambitious foray into systems biology. The department is a little more than a year old, has enrolled nine students in its Ph.D. program, and has assembled an impressive faculty led by chair Marc Kirschner, deputy chair Timothy Mitchison, and Lewis Cantley.
They were “the gang of three who believed sufficiently that something new was happening to come together and make this [department] happen,” says Gunawardena, who is the director of the Virtual Cell Program.
A self-professed “mathematician who fell from grace,” Gunawardena had stints in academia and industry, including a long stay at Hewlett-Packard doing industrial research. While at HP, he caught the biology bug and moved to Harvard’s Bauer Center for Genomic Research. That was his first opportunity, he says, “to actually live among biologists and understand what was going on. Pretty much everything I thought before I came [to Bauer] turned out to be...modified substantially.” When ideas for the new systems biology department bubbled up, he was invited to join.
Mallavarapu is a cell biologist and biochemist by training. He took his Ph.D. with Mitchison at the University of California, San Francisco, working on photomarking technologies to visualize cytoskeletal dynamics. During the past few years, Mallavarapu worked at Millennium Pharmaceuticals developing technology, writing software, and thinking about what is now b. He credits conversations with Gunawardena for stoking his desire to make the language a reality, and he recently joined the Virtual Cell Program as a research scientist. These guys have great jobs!
Certainly, tricky issues remain. Defining b so that it can be easily compiled on various LISP platforms isn’t trivial. Attracting an early adopter community will be important. Writing an easy-to-use graphical user interface is another priority, as is getting models and modeling techniques published in peer-reviewed literature.
“I think [it’s] the classical catch-22 problem: Until there’s a community of people speaking [a language], why would you want to learn it?” Gunawardena says. “I’m very keen on little b in the context of some courses that we’ll be teaching [and] think that’s going to be a very influential early adopter community. I think it’s likely that some of our colleagues at the medical school and also at MIT are very interested.”
It will be interesting to watch how big little b becomes.